Back

Female gender is an independent predictor of clinical benefit from cardiac resynchronisation therapy - results from the BIOWOMEN study

28 August 2023 (16:15 - 16:50)
Organised by: Logo
Congress Presentation Part of: New insights into cardiac resynchronisation therapy and remote monitoring Cardiac Resynchronisation Therapy (CRT) ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Lieselot Van Erven

Leiden University Medical Center, Leiden (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Biventricular or conduction system pacing for cardiac resynchronization therapy: a proposed treatment algorithm based on interventricular conduction delays
Doctor F. Landra (Cuneo, IT)
Abstract Slides Video
Presentation thumbnail
Associations of 2013 and 2021 ESC definitions of left bundle-branch block with mechanical dyssynchrony and CRT-induced reverse remodeling
Doctor A. Beela (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Personalized cardiac resynchronization therapy guided by real-time electrocardiographic imaging for non-left bundle branch block patients
Doctor M. Tam (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Left ventricular anterolateral site is the preferable left ventricular lead position for an upgrade to biventricular pacing
Doctor M. Ogano (Shizuoka, JP)
Abstract Slides Video
Presentation thumbnail
Fragmented QRS complex as a predictor of all-cause mortality in patients undergoing cardiac resynchronization therapy
Doctor J. Esteban Chapel (Madrid, ES)
Abstract Slides Video

Access the full session

Session thumbnail
New insights into cardiac resynchronisation therapy and remote monitoring

The Event

Event poster

ESC Congress 2023

28 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiac resynchronization therapy: better in women?
thumbnail
Congress Presentation
Cardiac resynchronization therapy: better in women?
thumbnail
Congress Presentation
Cardiac resynchronization therapy outcomes by patient sex and baseline QRS duration: insights from AdaptResponse

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources